Wealth Manager at Shard Capital Stockbrokers, Simon Niven, provides some insights into the small pharmaceutical company sector.
Motif Bio PLC (AIM:MTFB) Motif Bio Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study
Motif Bio plc (AIM/NASDAQ: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced positive topline results from REVIVE-2, a global Phase 3 clinical trial evaluating the